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Abstract
Analyzing sets of genes in genome-wide association studies is a relatively new approach that aims to capitalize on
biological knowledge about the interactions of genes in biological pathways. This approach, called pathway
analysis or gene set analysis, has not yet been applied to the analysis of rare variants. Applying pathway analysis
to rare variants offers two competing approaches. In the first approach rare variant statistics are used to generate
p-values for each gene (e.g., combined multivariate collapsing [CMC] or weighted-sum [WS]) and the gene-level
p-values are combined using standard pathway analysis methods (e.g., gene set enrichment analysis or Fisher’s
combined probability method). In the second approach, rare variant methods (e.g., CMC and WS) are applied
directly to sets of single-nucleotide polymorphisms (SNPs) representing all SNPs within genes in a pathway. In this
paper we use simulated phenotype and real next-generation sequencing data from Genetic Analysis Workshop
17 to analyze sets of rare variants using these two competing approaches. The initial results suggest substantial
differences in the methods, with Fisher’s combined probability method and the direct application of the WS
method yielding the best power. Evidence suggests that the WS method works well in most situations, although
Fisher’s method was more likely to be optimal when the number of causal SNPs in the set was low but the risk
of the causal SNPs was high.
Background
Analysis of single-nucleotide polymorphism (SNP)
microarray data in genome-wide association studies has
traditionally been agnostic because prior biological
knowledge about the genome has not been taken into
account. However, as the biological knowledge base
increases, it is increasingly common to use a priori bio-
logical knowledge in the analysis of SNP data. A
recently proposed approach to integrate biological
knowledge in the analysis of SNP data in genome-wide
association studies is pathway or gene set analysis [1-5].
Â In pathway analysis, SNPs are associated with genes,
and genes are placed into sets (commonly representing
biological pathways). Each set is then tested for associa-
tion with the phenotype. The driving force behind the
development of these methods is to increase the power
to identify causal SNPs while decreasing the multiple
testing penalties that arise when the hundreds of thou-
sands of SNPs typically involved in traditional genome-
wide association studies are tested. Increased power is
obtained by leveraging knowledge about relationships
between SNPs, genes, and sets or pathways. The evalua-
tion of significance at the gene set level allows investiga-
tors to identify genotype-phenotype associations that,
although not discernible on a SNP-by-SNP basis, are
evident through the amalgamation of SNPs into sets.
Pathway analysis methods have been successful in a
variety of applications (e.g., expression data, SNP micro-
array data). However, this approach has yet to be
applied to rare variant analysis of next-generation
sequence data. A variety of methods have been proposed
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for the analysis of rare variants [6-9]. All methods use
an approach in which genotype information at indivi-
dual rare variants is combined across variants within a
gene to yield a gene-level statistic. Madsen and Brown-
ing [6] suggested the possibility of combining rare var-
iant information across a set (pathway) of genes, and
this method has been recently applied to common var-
iants [10], but the approach has not yet been implemen-
ted in practice on rare variant data. In addition, this
approach has not been compared to traditional methods
of pathway analysis, which combine information at the
gene level into a gene statistic before combining over
the pathway.
In this paper we implement pathway analysis using
two opposing strategies. In the first strategy we create
sets of SNPs by combining all SNPs within genes in a
set or pathway of interest, and then we apply recently
proposed rare variant methods to these sets. In the sec-
ond strategy we use rare variant methods to generate a
statistic for each gene (combining information on all
rare variants in the gene) and then apply traditional
pathway analysis approaches to the gene-level statistics.
We compare the strategies by evaluating the type I error
rate and comparing statistical power under a variety of
different scenarios. Comparisons are made using simu-
lated phenotype data and real sequence data made avail-




All analyses presented here are based on data provided
by the organizers of GAW17. The data consist of 697
unrelated individuals from the 1000 Genomes Project
genotyped at 24,487 autosomal SNPs with minor allele
frequencies (MAFs) ranging from 7.17 × 10−4 to 0.499.
All SNPs are contained in at least one of 3,205 different
genes, and so the data can be considered a mini-exome
scan. The organizers of GAW17 simulated a dichoto-
mous phenotype for the 697 individuals. The dichoto-
mous disease phenotype is caused by a combination of
measured SNPs (160 SNPs in 36 genes) and unmeasured
SNPs. Two-hundred separate simulated phenotype repli-
cates (each based on the same disease model) were
produced.
Gene set construction
To evaluate the effectiveness of different approaches to
pathway analysis, we constructed 2,000 sets of 25 genes
with varying degrees of association with the phenotype.
The 2,000 sets fall into four broad categories: (1) Five
hundred sets contain some number C (C = 5, 10, 15, 20,
and 25) of genes known to contain SNPs causally related
to the phenotype (100 sets for each value of C). These
sets were created by first randomly choosing C genes
from the list of 36 causal genes and then randomly
choosing (25 − C) genes from the list of noncausal
genes. (2) Five hundred sets were created by randomly
selecting 25 genes from the list of noncausal genes. (3)
Five hundred sets were created by randomly selecting 25
genes from a list of noncausal genes that also did not
show evidence of spurious association with the pheno-
type. Spuriously associated genes are defined as noncau-
sal genes for which the number of replicates (out of
200) that yield a p-value less than 0.05 for the gene,
using both the combined multivariate collapsing (CMC)
and weighted-sum (WS) methods (see [11]), is more
than 15. (4) The five hundred sets described in category
1 were modified so that the (25 − C) noncausal genes in
the set were selected from a list of genes that were also
not spurious [11].
Rare variant methods
We used two different rare variant methods in our ana-
lyses: the WS method [6] and the CMC method [7].
Details of our implementations of the WS and CMC
methods are provided by Luedtke et al. [11]. One thou-
sand phenotype permutations were used to assess the
significance of the WS statistic, whereas for the CMC
method we used the asymptotic distribution of Hotell-
ing’s T2 statistic to assess statistical significance.
Pathway analysis
The traditional approach to pathway analysis is to first
generate gene scores and then to aggregate the gene
scores across all genes in a set; an alternative approach
is to aggregate SNPs into sets directly. To implement
the gene score aggregation approaches, we use the p-
values generated by applying the WS and CMC methods
to each of the 3,205 genes under study and then use one
of three different approaches: (1) Gene set enrichment
analysis (GSEA; weighted Kolmogorov-Smirnov test)
[12] was implemented on the distribution of negative
log p-values; (2) a Kolmogorov-Smirnov (KS) test was
applied directly to the negative log p-value distribution
of genes in the set and not in the set; (3) Fisher’s com-
bined probability test (Fisher’s method) was also used
on the p-values of the genes in the set of interest. We
also applied the WS and CMC methods directly to sets
of SNPs. Significance of GSEA and the WS method is
found using phenotype permutation, whereas other
methods use asymptotic distributions.
Results
Type I error
The first step in comparing the eight methods for path-
way analysis involved comparing the type I error rates
of the eight methods on 500 sets that did not contain
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any truly causal SNPs (see Table 1). Although four of
the eight methods controlled type I error well, the other
four methods saw substantial type I error rates. We also
created 500 additional null sets that did not contain any
genes showing spurious association with the phenotype
across the 200 replicates (see Methods section for
details). All methods controlled type I error on these
sets.
Power
Next we explored the power of the eight different meth-
ods. Because of inflation of the type I error rate as a
result of genes showing spurious association with the
phenotype, we chose to analyze the power of only the
500 sets containing truly causal genes and noncausal
genes that also did not show spurious association with
the phenotype. Figure 1 illustrates the power of the
eight methods across gene sets containing between 0
and 25 causal genes in the set of 25 genes. Direct appli-
cation of the WS approach showed better average power
than all other methods across sets containing from 5–25
causal genes. The WS-Fisher method and the CMC-
Fisher method substantially outperformed the other
methods. All methods showed power gains as the num-
ber of genes associated with the phenotype increased.
Because the sets do not contain spuriously associated
genes, all methods show accurate control or overly con-
servative control of the type I error rate.
Relationships between power and set characteristics
For each set and method combination, we calculated the
number of times out of 200 that the set was identified
as significant (a = 0.05) for the method. For each set,
we then looked at which method identified the set as
significant the most times out of 200. The WS-GSEA,
WS-KS, CMC-GSEA, and CMC-KS methods were not
optimal for any of the 500 sets, and so we eliminated
those methods from further analysis. Furthermore, the
CMC method was best for only five sets, and the aver-
age increase in power for the remaining three methods
was only 2.9% (SD = 1.8%). Because this was only a
marginal increase, we eliminated the CMC method from
further consideration, leaving three methods under con-
sideration: WS, WS-Fisher, and CMC-Fisher, which
were also the three methods that consistently yielded
the highest average power across all sets (see Figure 1).
Each of the three methods had particular sets for
which it was optimal: The WS method yielded the high-
est power for 429 of the 500 sets, the WS-Fisher
method for 44 of the 500 sets, and the CMC-Fisher
method for 27 of the 500 sets. For the 27 sets for which
the CMC-Fisher method was best, the average power
increase was 8.0% (SD = 7.9%) compared to the WS
method and 13.4% (SD = 10.6%) compared to the WS-
Fisher method. For the 44 sets for which the WS-Fisher
method was best, the average power increase was 9.8%
(SD = 9.7%) compared to the WS method. In the rest of
this section, we attempt to characterize the sets found
to be optimal by each method to provide insight into
the strengths and weaknesses of each approach.
A logistic regression model was fitted to predict
whether the WS method was the best. The model used
five explanatory variables: (1) number of causal genes in
the set, (2) number of causal SNPs in the set, (3) total
number of SNPs in the set, (4) average MAF for asso-
ciated genes in the set (MAFs for causal SNPs were first
summed within genes), and (5) weighted risk score (sum
of pairwise products of MAF and b for each causal SNP
in the set; b is the true risk of the SNP on the pheno-
type). In the model, two of the five variables were signif-
icant (p < 0.01): the weighted risk score (p = 1.5 × 10−7)
was negatively associated, whereas the number of causal
Table 1 Type I error rates across the five approaches for the 500 null sets and the 500 nonspurious gene sets
Pathway method Across 500 null sets Across 500 nonspurious gene sets
Nominal a = 0.05 Nominal a = 0.005 Nominal a = 0.05 Nominal a = 0.005
No gene-level aggregation
WS 0.492 0.190 0.043 0.004
CMC 0.232 0.054 0.037 0.003
Gene-level aggregation
WS-GSEA 0.048 0.004 0.001 0.000
WS-KS 0.040 0.003 0.000 0.000
WS-Fisher 0.429 0.244 0.010 0.004
CMC-GSEA 0.063 0.007 0.002 0.000
CMC-KS 0.044 0.004 0.004 0.000
CMC-Fisher 0.484 0.235 0.048 0.006
WS, weighted sum; CMC, combined multivariate collapsing; GSEA, gene set enrichment analysis; KS, Kolmogorov-Smirnov test; Fisher, Fisher’s combined
probability test.
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SNPs (p = 4.8 × 10−7) was positively associated. Thus
overall the WS method did better than the Fisher meth-
ods when the number of causal SNPs in the set was
higher and the weighted risk score was lower, this being
a situation of consistently small associations in the set.
The Fisher methods did better in situations in which
there were only a few strong associations in the set.
Discussion
Overall, we find substantial differences in power and
type I error rates between the different methods, with
the WS, WS-Fisher, and CMC-Fisher methods having
the highest power while controlling the type I error rate.
However, type I error control occurs only with the elim-
ination of spurious genes, which have been identified by
others [11], and may be associated with the phenotype
as a result of gametic phase disequilibrium and popula-
tion stratification. Two popular methods of conducting
gene set analysis (GSEA and the KS test) perform poorly
relative to Fisher’s method and direct application of rare
variant statistics to sets of SNPs.
As noted, when spuriously associated genes are
removed from sets, type I error rates are well controlled
by all methods (including the WS and WS-Fisher
methods), suggesting that if spurious associations are
better handled by rare variant methods, type I errors
should be well controlled. As shown by Luedtke et al.
[11], proper handling of population stratification elimi-
nates some of the spurious associations. However, some
spurious association still remains, and it tends to be
associated with genes that show higher gametic phase
disequilibrium with causal genes. Although some meth-
ods can handle population stratification, other methods
are needed to control gametic phase disequilibrium. It is
important to note that our results suggest a lack of con-
trol of the type I error rate in practice. Furthermore, we
note that the apparent overconservative nature of some
of the methods for sets that eliminate spurious genes is
due to the elimination of genes, suggesting that spurious
association reduces the amount of variability in noncau-
sal genes.
Conclusions
Although the WS method outperforms the WS-Fisher
and CMC-Fisher methods in the aggregate, the Fisher
methods improve their relative performance when the
number of causal SNPs is low and the weighted risk
score of the set is high. This situation occurs when a
Figure 1 Power of pathway analysis methods across gene sets with varying numbers of associated genes
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few strongly associated genes or SNPs are present in a
set but most of the set is not associated with the pheno-
type. Further analysis with a more comprehensive set of
simulated and real sets is needed to fully explore the
advantages and disadvantages of the WS method relative
to the WS-Fisher and CMC-Fisher methods. It is parti-
cularly important to note that the Fisher methods may
still be necessary and useful for pathway analysis
because in many real-life applications of pathway analy-
sis only a small fraction of a set may actually be asso-
ciated with the phenotype.
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